'Mosaic' HIV vaccine from J&J and partners passes early test

Fierce Pharma ------- The decades-long quest for a successful HIV vaccine has yielded plenty of failures, but with new early-stage results announced Monday, Johnson & Johnson and its partners hope they might have a winner. J&J touted the phase 1/2a study results early Monday, announcing that an investigational shot appeared to be well-tolerated and elicited HIV-1 antibody responses in all participants. The study tested a “mosaic” HIV vaccine in nearly 400 patients across the U.S, Rwanda, Uganda, South Africa and Thailand. Speaking with FiercePharma ahead of the data release, lead investigator Dan Barouch said the vaccine is designed using computer sequencing to protect against HIV subtypes all over the world. Other HIV vaccine programs have aimed at protecting against the virus in different global regions, he said, limiting how they would be deployed. To learn more click on the picture below to read the article.